The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia
Background: In the treatment of childhood acute lymphoblastic leukemia (ALL), 6-mercaptopurine (6-MP) is essential for early intensification and maintenance of therapy. Recently, an association between genetic variants of nudix hydrolase 15 (NUDT15) rs116855232 and 6-MP-induced severe myelotoxicity...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Elsevier
2023-01-01
|
| سلاسل: | EJC Paediatric Oncology |
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://www.sciencedirect.com/science/article/pii/S2772610X23000041 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
